Transcription of Federal Guidelines for Opioid Treatment Programs
{{id}} {{{paragraph}}}
Example: biology
Federal Guidelines for Opioid Treatment Programs
0 TABLE OF CONTENTS Federal Guidelines FOR Opioid Treatment Programs January 2015 Federal Guidelines FOR Opioid Treatment Programs Acknowledgments This publication was prepared for under contract number HHSS28320070053I/HHSS28342003T by the Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS). Nichole Washington Smith served as the Government Project Officer. Disclaimer The views, opinions, and content expressed herein are the views of the consensus panel members and do not necessarily reflect the official position of SAMHSA or HHS. No official support of or endorsement by SAMHSA or HHS for these opinions or for the instruments or resources described are intended or should be inferred.
opioid drugs for the treatment of opioid addiction. As stated in 42 CFR § 8.12(i)(2), these regulations apply to “opioid agonist treatment medications that are approved by the Food and Drug Administration.” Currently, these drugs are methadone and pharmaceutical products containing buprenorphine, hereafter referred to as buprenorphine.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Policies, Methadone Maintenance, Treatment, Methadone Maintenance Treatment, Methadone Treatment, Methadone, Medication Treatment Guidelines for Substance, Medication Treatment Guidelines for Substance Use Disorders (SUDs) - Transmucosal Buprenorphine, Chronic Pain, Substance Abuse and Mental Health Services Administration, Clinical Guidelines: Treatment of Opioid Dependence